The aim of this non-interventional study is to describe patient's perception of anticoagulant
treatment when using Pradaxa® to prevent stroke and systemic embolism while suffering from
atrial fibrillation (according to its approved indication in the approved dosages of 110 mg
or 150 mg twice daily) in comparison to standard care using Vitamin K Antagonist (VKA).